Ethnic and socioeconomic disparities in initiation of second‐line antidiabetic treatment for people with type 2 diabetes in England: A cross‐sectional study
Authors' conclusion
Among people with T2DM, there were no substantial differences by ethnicity or deprivation level in the percentage prescribed either SGLT2 inhibitors, DPP-4 inhibitors or SUs as second-line antidiabetic treatment.
Study context
- Population
- People aged ≥18 years with T2D in England who intensified to second-line oral antidiabetic medication (SU, DPP-4i or SGLT2i with metformin) 2014–2020
- Participants
- 36,023 people
- Exposure
- Second-line antidiabetic treatment prescribing by ethnicity and deprivation level
- Outcome
- Predicted percentage prescribed SGLT2i, DPP-4i or SU as second-line treatment, by ethnicity and deprivation
Methodological detailslinked primary and secondary care data (CPRD, HES, Index of Multiple Deprivation (IMD)), multivariable multinomial logistic regression
- Linked primary and secondary care data (CPRD, HES, IMD)
- Multivariable multinomial logistic regression
Main finding
As reported in the abstract
Adjusted predicted percentage prescribed SGLT2i, by ethnicity
Observational data: associations, not effects.
Further findings
Percent
Least deprived
22%(95% CI 20–25%)
Most deprived
19%(95% CI 17–21%)
SGLT2i prescribing stratified by prevalent cardiovascular disease (CVD)
- Lower predicted percentages prescribed SGLT2i with prevalent CVD vs without, across all ethnicity groups and deprivation levels
Original publication
Ethnic and socioeconomic disparities in initiation of second‐line antidiabetic treatment for people with type 2 diabetes in England: A cross‐sectional study. Diabetes Obes Metab. Published 2 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →